Dantrolene sodium in spasticity. Long-term administration in children

G. E. Molnar, L. A. Evangelista, Dona Rani C. Kathirithamby

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This article reports on 27 children with spasticity caused by cerebral palsy and other nonprogressive neurologic conditions who received dantrolene sodium for a mean period of 16 months, with a range of 4 to 41 months; age varied from 2 to 14 years at the onset of treatment. All children showed some degree of favorable change, although statistically significant improvement could be demonstrated only in certain neurologic signs. Dosage ranged from 1 to 8.5 mg per kilogram per day. On long-term treatment, the usual daily dose was 2 to 5 mg per kilogram. Clinical side-effects were mild and transient. Laboratory examinations showed temporary abnormality of liver-function tests in six children. In an additional case, persistent abnormal test findings led to discontinuation of treatment.

Original languageEnglish (US)
Pages (from-to)1233-1237
Number of pages5
JournalNew York state journal of medicine
Volume78
Issue number8
StatePublished - 1978

Fingerprint

Dantrolene
Liver Function Tests
Cerebral Palsy
Neurologic Manifestations
Nervous System
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dantrolene sodium in spasticity. Long-term administration in children. / Molnar, G. E.; Evangelista, L. A.; Kathirithamby, Dona Rani C.

In: New York state journal of medicine, Vol. 78, No. 8, 1978, p. 1233-1237.

Research output: Contribution to journalArticle

@article{f93b9ee6e43a4279bace56446de08fdc,
title = "Dantrolene sodium in spasticity. Long-term administration in children",
abstract = "This article reports on 27 children with spasticity caused by cerebral palsy and other nonprogressive neurologic conditions who received dantrolene sodium for a mean period of 16 months, with a range of 4 to 41 months; age varied from 2 to 14 years at the onset of treatment. All children showed some degree of favorable change, although statistically significant improvement could be demonstrated only in certain neurologic signs. Dosage ranged from 1 to 8.5 mg per kilogram per day. On long-term treatment, the usual daily dose was 2 to 5 mg per kilogram. Clinical side-effects were mild and transient. Laboratory examinations showed temporary abnormality of liver-function tests in six children. In an additional case, persistent abnormal test findings led to discontinuation of treatment.",
author = "Molnar, {G. E.} and Evangelista, {L. A.} and Kathirithamby, {Dona Rani C.}",
year = "1978",
language = "English (US)",
volume = "78",
pages = "1233--1237",
journal = "New York state journal of medicine",
issn = "0028-7628",
number = "8",

}

TY - JOUR

T1 - Dantrolene sodium in spasticity. Long-term administration in children

AU - Molnar, G. E.

AU - Evangelista, L. A.

AU - Kathirithamby, Dona Rani C.

PY - 1978

Y1 - 1978

N2 - This article reports on 27 children with spasticity caused by cerebral palsy and other nonprogressive neurologic conditions who received dantrolene sodium for a mean period of 16 months, with a range of 4 to 41 months; age varied from 2 to 14 years at the onset of treatment. All children showed some degree of favorable change, although statistically significant improvement could be demonstrated only in certain neurologic signs. Dosage ranged from 1 to 8.5 mg per kilogram per day. On long-term treatment, the usual daily dose was 2 to 5 mg per kilogram. Clinical side-effects were mild and transient. Laboratory examinations showed temporary abnormality of liver-function tests in six children. In an additional case, persistent abnormal test findings led to discontinuation of treatment.

AB - This article reports on 27 children with spasticity caused by cerebral palsy and other nonprogressive neurologic conditions who received dantrolene sodium for a mean period of 16 months, with a range of 4 to 41 months; age varied from 2 to 14 years at the onset of treatment. All children showed some degree of favorable change, although statistically significant improvement could be demonstrated only in certain neurologic signs. Dosage ranged from 1 to 8.5 mg per kilogram per day. On long-term treatment, the usual daily dose was 2 to 5 mg per kilogram. Clinical side-effects were mild and transient. Laboratory examinations showed temporary abnormality of liver-function tests in six children. In an additional case, persistent abnormal test findings led to discontinuation of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0018138870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018138870&partnerID=8YFLogxK

M3 - Article

C2 - 97602

AN - SCOPUS:0018138870

VL - 78

SP - 1233

EP - 1237

JO - New York state journal of medicine

JF - New York state journal of medicine

SN - 0028-7628

IS - 8

ER -